NCT04538066: A trial that was reported late by Neurotrope Bioscience, Inc.
This trial has reported, although it was 41 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04538066 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 30, 2020 |
| Completion date | Nov. 16, 2022 |
| Required reporting date | Nov. 16, 2023, midnight |
| Actual reporting date | Dec. 27, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 41 |